Every Form 4 that Immunocore Holdings plc (IMCR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IMCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMCR filings page.
Immunocore Holdings plc director Peter John Ratcliffe received a new stock option grant. On May 27, 2026, he was granted options over 27,492 ordinary shares at an exercise price of $28.52 per share, with no cash paid for the grant itself.
The options expire on May 26, 2036 and represent his entire reported option position of 27,492 options following this transaction. According to the terms, the award will vest at the earlier of May 27, 2027 or the day immediately prior to Immunocore’s next annual general meeting, provided he continues in service through the vesting date.
Immunocore Holdings plc reported that director Kristine Peterson received a stock option grant covering 27,492 ordinary shares. The options have an exercise price of $28.52 per share and expire on May 26, 2036. The award vests at the earlier of May 27, 2027 or the day immediately prior to the company’s next annual general meeting, contingent on her continued service. This is a compensation-related award rather than an open-market share purchase or sale.
Immunocore Holdings plc director William Pao received a new stock option grant. The award covers 27,492 options to buy Ordinary Shares at an exercise price of $28.52 per share, expiring on May 26, 2036.
The options vest at the earlier of May 27, 2027, or the day immediately before Immunocore’s next annual general meeting, as long as Pao remains in continuous service through the vesting date. Following this grant, he holds 27,492 share options directly.
Immunocore Holdings plc director Siddharth Kaul received a grant of share options for 27,492 ordinary shares. The options carry an exercise price of $28.52 per share and expire on May 26, 2036, providing long-term equity-based compensation.
The award vests at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, as long as Kaul remains in continuous service until that vesting date. This is a compensation-related grant, not an open-market share purchase or sale.
Immunocore Holdings plc director Roy Steven Herbst received a grant of 27,492 share options to buy ordinary shares. The options have an exercise price of $28.52 per share and expire on May 26, 2036, according to the Form 4.
The award vests at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, provided he remains in continuous service through the vesting date. After this grant, the filing shows 27,492 derivative securities held directly.
Immunocore Holdings plc director John Irving Bell received a grant of 27,492 share options. Each option gives the right to buy one ordinary share at an exercise price of $28.52 and expires on May 26, 2036. According to the terms, the options vest at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, provided he remains in continuous service until that vesting date. Following this award, he holds 27,492 derivative securities linked to ordinary shares.
Coy Travis Alan reported acquisition or exercise transactions in this Form 4 filing.
Immunocore Holdings plc reported that Chief Financial Officer Travis Alan Coy received new equity awards. On February 17, 2026, he was granted 33,353 Restricted Share Units, each representing a contingent right to receive one Ordinary Share, which vest in four equal annual installments starting February 17, 2027, subject to continuous service.
He was also granted an option over 95,637 shares, with 25% vesting on February 17, 2027 and 6.25% vesting in quarterly installments thereafter, also subject to continuous service. Ordinary Shares may be represented by American Depositary Shares, with each ADS equal to one Ordinary Share.
Immunocore Holdings plc chief executive officer Bahija Jallal reported several equity transactions. She sold 11,474 Ordinary Shares in an open-market transaction at a weighted average price of $32.35 per share, under a sell-to-cover arrangement to pay income taxes triggered by vesting restricted share units.
On a separate date, she acquired 23,817 Ordinary Shares at no cost through the exercise of Restricted Share Units, with each RSU converting into one Ordinary Share. She was also granted 88,573 new RSUs and 395,066 employee share options, each award vesting in scheduled installments starting in February 2026 or February 2027, contingent on continued service.
Immunocore Holdings plc executive John Goll reported both equity awards and a small tax-related share sale. As SVP, Finance & CAO, he sold 698 Ordinary Shares on February 18, 2026 in an open-market transaction at a weighted average price of $32.35 per share under a sell-to-cover arrangement to satisfy income tax liabilities from vesting restricted share units (RSUs).
On February 17, 2026, he acquired 1,351 Ordinary Shares through the exercise of RSUs, and received grants of 7,411 additional RSUs and 21,252 employee share options. The new RSUs and options vest in equal annual and quarterly installments beginning in February 2027, subject to his continuous service.
Immunocore Holdings plc reported insider transactions by Chief HR Officer Tina Amber St Leger. On February 18, 2026, she completed an open-market sale of 1,000 Ordinary Shares at a weighted average price of $32.35 per share, under a sell-to-cover arrangement to satisfy income tax liabilities from restricted stock unit vesting.
On February 17, 2026, 2,119 Restricted Share Units were exercised and converted into 2,119 Ordinary Shares at no cost, with each RSU representing one Ordinary Share. After these transactions, she directly held 1,119 Ordinary Shares and 6,357 RSUs.
Immunocore Holdings plc’s Head of R&D, David M. Berman, reported RSU vesting, share issuance and a related tax sale. On February 17, 2026, he exercised 11,824 Restricted Share Units, receiving the same number of Ordinary Shares at a $0.00 exercise price.
On February 18, 2026, he conducted an open-market sale of 5,965 Ordinary Shares at a weighted average price of $32.35 per share, under a sell-to-cover arrangement to satisfy income tax liabilities from RSU vesting. After these transactions, he directly held 5,859 Ordinary Shares and 35,473 RSUs. Each RSU and each American Depositary Share represents one Ordinary Share.
Immunocore Holdings plc (IMCR) reported insider transactions by its Head of R&D on Form 4. On November 24-25, 2025, the officer exercised employee share options with an exercise price of $17.46 per ordinary share and immediately sold the same number of shares in the market.
The transactions included exercising and selling 100 ordinary shares on November 24 at a sale price of $40.00 per share, and exercising and selling 18,020 ordinary shares on November 25 at a weighted average sale price of $40.03 per share. After these sales, the reporting person held no ordinary shares directly but continued to hold employee share options, including 118,670 options immediately exercisable and expiring on September 12, 2028. All trades were made under a Rule 10b5-1 trading plan adopted on May 9, 2025.